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ABSTRACT
Objective To examine familial aggregation of gout and
to estimate the heritability and environmental
contributions to gout susceptibility in the general
population.
Methods Using data from the National Health
Insurance (NHI) Research Database in Taiwan, we
conducted a nationwide cross-sectional study of data
collected from 22 643 748 beneﬁciaries of the NHI in
2004; among them 1 045 059 individuals had
physician-diagnosed gout. We estimated relative risks
(RR) of gout in individuals with affected ﬁrst-degree and
second-degree relatives and relative contributions of
genes (heritability), common environment shared by
family members and non-shared environment to gout
susceptibility.
Results RRs for gout were signiﬁcantly higher in
individuals with affected ﬁrst-degree relatives (men, 1.91
(95% CI 1.90 to 1.93); women, 1.97 (95% CI 1.94 to
1.99)) and also in those with affected second-degree
relatives (men, 1.27 (95% CI 1.23 to 1.31); women,
1.40 (95% CI 1.35 to 1.46)). RRs (95% CIs) for
individuals with an affected twin, sibling, offspring,
parent, grandchild, nephew/niece, uncle/aunt and
grandparent were 8.02 (6.95 to 9.26), 2.59 (2.54 to
2.63), 1.96 (1.95 to 1.97), 1.93 (1.91 to 1.94), 1.48
(1.43 to 1.53), 1.40 (1.32 to 1.47), 1.31 (1.24 to
1.39), and 1.26 (1.21 to 1.30), respectively. The relative
contributions of heritability, common and non-shared
environmental factors to phenotypic variance of gout
were 35.1, 28.1 and 36.8% in men and 17.0, 18.5 and
64.5% in women, respectively.
Conclusions This population-based study conﬁrms that
gout aggregates within families. The risk of gout is
higher in people with a family history. Genetic and
environmental factors contribute to gout aetiology, and
the relative contributions are sexually dimorphic.
INTRODUCTION
Gout is the most common inﬂammatory joint
disease1–4 with an impact on morbidity5–7 and pre-
mature mortality.8–10 The disease is heritable, as
suggested by familial clustering of the disease;11–20
however, the existence of many known risk factors,
such as male gender, increasing age,21 22 obesity,23
chronic renal impairment,24 hypertension,25 26
long-term use of diuretics27 and certain diets with
high purine28 and alcohol,29 also supports a strong
environmental contribution. Currently, the balance
between genetic and environmental contributions is
still unclear.
High heritability of hyperuricaemia,30 the main
driver of urate crystal deposition and the develop-
ment of gout, has led to efforts to identify susceptibil-
ity genes. A large familial segregation study has
demonstrated signiﬁcant heritability for hyperuricae-
mia30 and speciﬁc genetic associations, particularly
genes involved in renal urate clearance, have been
identiﬁed that mechanistically might explain genetic
susceptibility to hyperuricaemia.31–34 Despite the
strong evidence supporting a genetic contribution to
hyperuricaemia, studies concerning the relative
contributions of genetic and environmental factors to
gout are rare. A complex segregation analysis
conducted in aborigines in Taiwan showed a substan-
tial genetic component for gout,35 but a recent classic
twin study, with 514 all-male twin pairs in the US,
paradoxically found signiﬁcant heritability for hyper-
uricaemia but not for clinical gout.36 Additionally,
efforts largely failed to identify susceptibility genes
to gout beyond genes controlling serum urate con-
centration, thus questioning the role of genetic
factors in gout.34
Therefore, we undertook the ﬁrst nationwide
population-based study to estimate the degree of
familial aggregation of gout and the extent to
which heritability and a common familial environ-
ment might each account for familial aggregation.
We studied this in Taiwan because, ﬁrst, Taiwan has
one of the highest reported estimates of gout preva-
lence worldwide37 and, second, there is an estab-
lished nationwide health insurance database
containing sufﬁcient demographic, family history
and medical data on the entire Taiwanese popula-
tion to allow us to address these questions.
METHODS
The study was approved by the Institutional
Review Board of Chang Gung Memorial Hospital
(approval number 101-2178C).
Source of data
The primary data source came from the National
Health Insurance Research Database (NHIRD),
which contains registration information and ori-
ginal claims data on all beneﬁciaries of NHI in
Taiwan since its establishment in 1995. All entries
for an individual are linked by a unique personal
identiﬁer assigned to each Taiwanese resident,
which allows accurate linkage of records from the
Open Access
Scan to access more
free content
Clinical and epidemiological research
Kuo C-F, et al. Ann Rheum Dis 2015;74:369–374. doi:10.1136/annrheumdis-2013-204067 369
group.bmj.com on April 13, 2017 - Published by http://ard.bmj.com/Downloaded from 
registration ﬁles and from the original claims data. Before
release for research, personal identiﬁers are deidentiﬁed to
ensure conﬁdentiality.
The registry of beneﬁciaries, one of the registration ﬁles, con-
tains details of demographics, residence, kinship relationships,
occupation categories, insurance status and insurance amount of
all beneﬁciaries of NHI. Claims data on all outpatient visits,
inpatient care and pharmacy dispensing were recorded in spe-
ciﬁc datasets with information, such as dates of events, medical
diagnoses, medical expenditure and details of prescriptions,
operations, examinations and procedures.
Study population and classiﬁcation
The study population consisted of all NHI beneﬁciaries
(11 360 576 men; 11 283 172 women) in 2004, representing
99.8% of the total population of Taiwan at the end of 2004.38
Enrolled individuals were classiﬁed according to the affection
status of gout of their ﬁrst-degree and second-degree relatives
who were registered in the NHI before 2004.
Identiﬁcation of cases with gout
The primary case deﬁnition of gout was having a physician-
recorded diagnosis of gout (International Classiﬁcation of
Diseases, Ninth Revision [ICD-9] code: 274.x) together with at
least one prescription containing gout-speciﬁc medications (col-
chicine, benzbromarone, allopurinol, probenecid, sulﬁnpyra-
zone) at either an outpatient or emergency visit during 2000–
2004. An alternative deﬁnition, used for sensitivity analysis, was
having two outpatient or emergency visits with a physician-
recorded diagnosis of gout during 2000–2004. An identical case
deﬁnition of gout was used for all individuals and their
relatives.
Identiﬁcation of ﬁrst-degree and second-degree relatives
and family ascertainment
The registry of beneﬁciaries speciﬁes relationships between the
insured person who pays the fee, and his/her dependents, allow-
ing parent-offspring relationships and spouses to be identiﬁed
directly. Among 28 402 865 individuals registered with the NHI
during 1996–2010, 21 009 551 pairs of parent-offspring rela-
tionships were identiﬁed. Full siblings were identiﬁed as indivi-
duals who shared the same parents. Twins were full siblings who
have the same date of birth (±1 day). Second-degree relatives
were ascertained based on the aforementioned relationships.
These links allowed the identiﬁcation of 4 191 274 families
spanning 2–5 generations.
Demographics and socioeconomic information
We also incorporated socioeconomic factors, including resi-
dence, occupations and income levels, to reﬂect population
stratiﬁcation with the aboriginals (with signiﬁcantly higher
prevalence of gout39) and Han people in Taiwan. For details of
these factors, please refer to the online supplementary materials.
Statistical analysis
The prevalence of gout was calculated for the general popula-
tion and for individuals who had an affected spouse and/or
affected relatives. Any individual fulﬁlling the case deﬁnitions of
gout was deﬁned as a prevalent case. For prevalence of gout in
individuals with affected ﬁrst-degree and second-degree rela-
tives, age and sex were taken into account and age-standardised
and sex-standardised prevalence (95% CI) was determined. The
standard population used was the general population of Taiwan
in 2004.
The degree of familial aggregation of gout was estimated
using the relative risk (RR), which was calculated as the adjusted
prevalence ratio between individuals with affected relatives and
the entire population of Taiwan in 200440 The marginal Cox
proportional hazard model with an equal follow-up time for all
subjects with robust sandwich estimate,41 42 adjusted for age,
place of residence, income, occupation and family size, was used
to optimise the estimate of the RR. Because case clustering
within a family may occur, the robust sandwich estimate was
used when calculating conﬁdence bounds.41 The RR was esti-
mated for individuals with different family relatives affected
with gout, including ﬁrst-degree and second-degree relatives
affected, and for the number of affected ﬁrst-degree relatives
(father, mother, son, daughter, brother, sister).
We used the standard ACE model to examine the inﬂuences
of additive genetic (A), common environmental factors shared
by family members (C) and non-shared environmental factors
(E) accounting for variance in a phenotype (P). This model can
be expressed as:
s2P ¼ s2A þ s2C þ s2E
where σp
2=total phenotypic variance; σc
2=common environmen-
tal variance; σc
2=common environmental variance and σE
2=non-
shared environmental variance.
The heritability was deﬁned as the proportion of phenotypic
variance that is attributable to genetic factors and can be
expressed as s2A=s
2
p and the familial transmission was expressed
as ðs2A þ s2CÞ=s2p, which is the sum of heritability and common
environmental variances.
We used the polygenic liability model to calculate both mea-
sures.43–45 For details of this model, please see the online
supplementary material. We used the sibling RR, spouse RR and
the prevalence of gout in the general population (p) to calculate the
familial transmission and the heritability, which were expressed as
Familial transmission¼
T0T1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1ðT20T21Þð1ðT0=iÞÞ
q
aR½iþ T21ðiT0Þ
Heritability ¼
TsT1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1ðT2s T21Þð1ðTs=iÞÞ
q
aR½iþ T21ðiTsÞ
where T0¼F1 ð1pÞ; Ts¼F1 ð1 spouse RRpÞ;
T1¼F1ð1 siblingRRpÞ; p=prevalence of gout in the
normal population); aR: the additive genetic relationship between
the relatives, for full sibling, aR=0.5; i=z/p; z, the height of the
standard normal curve pertaining to gout prevalence, and Φ,
standard normal cumulative distribution function.46
Therefore, the common environmental component was the
difference between familial transmission and heritability. Since
the epidemiologic and clinical features of gout are sexually
dimorphic, and hence, equal genetic variances in both sexes
may not hold true,47 we estimated sex-speciﬁc familial transmis-
sion and heritability using respective sex-speciﬁc populations.
All analyses were performed for primary and alternative case
deﬁnitions of gout. A 2-sided p value 0.05 was considered statis-
tically signiﬁcant. All analyses were performed using SAS V.9.3
(SAS institute, Cary, North Carolina, USA).
RESULTS
Gout prevalence in individuals with affected family
members versus the general population
We identiﬁed 802 765 men and 242 294 women with gout in
2004 giving a crude prevalence of gout of 4.62% (95% CI
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4.61% to 4.63%) (see online supplementary table S1). Men had
a signiﬁcantly higher prevalence (7.07%, 95% CI 7.05% to
7.08%) than women (2.15%, 95% CI 2.14% to 2.16%). We
identiﬁed 1 663 904 individuals with at least one affected ﬁrst-
degree relative, and 604 468 individuals with at least one
affected second-degree relative. The standardised prevalence of
gout in individuals with affected ﬁrst-degree and second-degree
relatives were 13.37% (95% CI 13.35% to 13.39%) and
10.05% (95% CI 10.03% to 10.06%) in men, and 4.16% (95%
CI 4.15% to 4.18%) and 3.01% (95% CI 3.00% to 3.02%) in
women, respectively. Figure 1a and 1b show age-speciﬁc and
sex-speciﬁc prevalence of gout in men and women which, at all
ages, is higher in individuals with affected ﬁrst-degree relatives
than in those with second-degree relatives and the general
population.
Family exposure and risk of gout
The risk of gout was signiﬁcantly higher in individuals with
affected ﬁrst-degree relatives than in the general population, the
RRs being 1.91 (95% CI 1.90 to 1.93) in men and 1.97 (95%
CI 1.94 to 1.99) in women (see online supplementary table S2).
Individuals with affected second-degree relatives also had an
increased risk of gout, albeit signiﬁcantly lower than those with
affected ﬁrst-degree relatives, with RRs of 1.27 (95% CI 1.23 to
1.31) in men and 1.40 (95% CI 1.35 to 1.46) in women.
Figure 2 shows that individuals with an affected twin had the
highest risk, followed by individuals with an affected sibling,
then individuals with an affected offspring and, ﬁnally, indivi-
duals with an affected parent. Same-sex twins had the highest
RR, being higher in female-female twin pairs than male-male
twin pairs. The RRs for gout in individuals with any category of
affected second-degree relative (table 1) were lower than RRs in
those with affected ﬁrst-degree relatives (ﬁgure 2). The RRs also
increased with the number of affected ﬁrst-degree relatives.
Compared with the general population, individuals with one,
two or three or more categories of affected ﬁrst-degree relatives
had RRs (95% CIs) of 1.87 (1.86 to 1.89), 3.22 (3.15 to 3.29)
and 4.96 (4.64 to 5.30), respectively. This trend was more
prominent in women (ﬁgure 3).
Familial aggregation of gout was evident in individuals with
affected biological relatives, and also in those with affected
spouses. The RRs were 1.66 (1.65–1.68) in men with an
affected wife and 1.65 (95% CI 1.64 to 1.67) in women with
an affected husband.
Relative contributions of genetic, common and non-shared
environmental factors
To separate the inﬂuences of genes and environment, we calcu-
lated heritability and familial transmission. In men, heritability
was 35.1% (95% CI 34.1% to 36.0%) and familial transmission
was 63.2% (95% CI 61.8% to 64.7%); whereas in women, they
were 17.0% (95% CI 15.0% to 19.0%) and 35.5% (95% CI
33.1% to 37.8%), respectively. Figure 4 shows the relative con-
tributions of genetic (heritability), common environmental and
non-shared environmental components to the phenotypic var-
iances of gout.
Sensitivity analysis
We also used alternative case deﬁnition of gout to do sensitivity
analysis. The results were very similar to our primary analysis
(please see online supplementary table S3, ﬁgures S1 and S2).
DISCUSSION
This nationwide population study has conﬁrmed familial aggre-
gation of gout by demonstrating a greater prevalence and RR of
gout for individuals with affected family members compared to
the general population. The risk of gout is increased more by
having affected ﬁrst-degree relatives than having affected
second-degree relatives, and appears ‘dose-dependent’ in that
the risk increases with the number of affected relatives. These
results conﬁrm the long-held belief that gout clusters within
families and supports an important contribution of common
familial factors in predisposing to the development of gout.
However, biological relatives tend to share similar environ-
mental and lifestyle risk factors in addition to genes; both con-
tribute to familial aggregation. Therefore, we examined the risk
associated with having a spouse who has gout on the assump-
tion that any increased risk from this predominantly reﬂects pre-
disposition from environmental and lifestyle factors common to
family members. We found that the relative contributions differ
between men and women; however, overall it appears that
genetic factors play a smaller, but still substantial, role than
environmental factors in the aetiology of gout. Our ﬁndings are
consistent with the relative paucity of gout susceptibility genes
identiﬁed by genome-wide association studies in comparison
with greater numbers of genes associated with risk of hyperuri-
caemia, which has a greater heritability.31–34
Consistent with previous studies, our ﬁndings provide strong
evidence to support the existence of familial aggregation of
gout.11–19 However, current evidence concerning the relative
Figure 1 Age-speciﬁc prevalence of gout in men (A) and women (B) according to the affection status of relatives (red, individuals with affected
ﬁrst-degree relatives; green, individuals with affected second-degree relatives; blue, the general population).
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contributions of genetic and environmental exposures for gout
susceptibility is limited. A complex segregation study conducted
in the aborigines of Taiwan supported the existence of a sub-
stantial genetic predisposition to gout; however, no heritability
estimate was reported.35 By contrast, one recent study of 253
monozygotic and 261 dizygotic North American male twin
pairs found a signiﬁcant heritability for hyperuricaemia (49.6%)
but, surprisingly, given that chronic hyperuricaemia is the key
mechanism for urate crystal formation, no heritability (0%;
95% CI 0% to 61.8%) for gout.36 Nevertheless, our whole
population study provided several lines of evidence to support
the existence of genetic predisposition to gout. First, our data
on twin pairs showed signiﬁcantly different risk proﬁles in
same-sex twins compared to opposite-sex twins. Although lack
of information on zygosity prevented the calculation of herit-
ability based on twin data, the higher RR shared by same-sex
(partly monozygotic) twins compared to opposite-sex (exclu-
sively dizygotic) twins supports a genetic contribution. Second,
using the spouse as an indicator of shared environmental risk,
we estimated a heritability of 35.1% in men and 17.0% in
Figure 2 Relative risks (95% CI) of gout among (A) men and (B) women with affected ﬁrst-degree relatives (square, male; circle, female) in
comparison with the general population in Taiwan in 2004.
Table 1 Relative risk of gout among individuals with affected
second-degree relatives in comparison with the general population
in Taiwan in 2004
Affected second-degree
relatives
Men at risk Women at risk
RR 95% CI RR 95% CI
Grandparent
Grandfather 1.18 1.12 to 1.25 1.29 1.10 to 1.51
Grandmother 1.31 1.25 to 1.37 1.45 1.24 to 1.68
Grandchild
Grandson 1.25 1.20 to 1.31 1.45 1.39 to 1.52
Granddaughter 1.39 1.21 to 1.59 1.54 1.33 to 1.78
Uncle or aunt
Uncle 1.32 1.24 to 1.40 1.19 0.96 to 1.45
Aunt 1.21 0.98 to 1.48 0.91 0.41 to 2.03
Nephew or niece
Nephew 1.42 1.34 to 1.51 1.16 0.95 to 1.41
Niece 1.42 1.16 to 1.74 0.90 0.41 to 2.00
Figure 3 The ‘dose-response’ relationship between the numbers of
affected ﬁrst-degree relatives and relative risk of gout (blue: one; red:
two; green: three ﬁrst-degree relatives).
Clinical and epidemiological research
372 Kuo C-F, et al. Ann Rheum Dis 2015;74:369–374. doi:10.1136/annrheumdis-2013-204067
group.bmj.com on April 13, 2017 - Published by http://ard.bmj.com/Downloaded from 
women. Therefore, although not the sole explanation for famil-
ial aggregation, genetic factors in addition to environmental
inﬂuences, do contribute to the development of gout.
It has long been observed that men are signiﬁcantly more
likely to have gout than women.48 49 Additionally, onset of gout
is later in women.50 The cause of this sexual dimorphism is not
clear. One explanation is the uricosuric effect of oestrogen
which results in lower serum urate levels in premenopausal
women.51 Therefore, prevalence of gout is generally low in pre-
menopausal women and increases dramatically after meno-
pause.52 Different exposure to environmental risk factors may
also contribute to the sex difference. For instance, dietary
calorie intake and alcohol consumption are lower in women
than men in Taiwan according to a national nutrition
survey.53 54 Our study shows that familial transmission and her-
itability are both signiﬁcantly higher in men. These ﬁndings
suggest that genetic and common environmental factors are the
main predisposing factors to gout in men, but not in women.
Therefore, the sex difference can be partly attributed to differ-
ent contributions from family factors. Further study is needed
to conﬁrm this ﬁnding.
There are several limitations to the study. First, it was con-
ﬁned to Taiwan, so results may not be generalisable to other set-
tings. Second, the NHIRD is primarily a health insurance
database that contains limited information on criteria for clinical
diagnosis. We did not have data on potential confounding
factors, therefore, we cannot test the interactions between
family history and other confounders and their independent
contributions to the risk of gout. Further, our analysis of relative
genetic and environmental contributions was based on the
multifactorial liability model, and our results are subject to
assumptions, so should be interpreted with caution. However,
the published data on other disease, such as schizophrenia46
support the validity of this model. Finally, we cannot account
for the effects of assortative mating whereby spouses are more
similar for a phenotype than they would be if mating occurred
at random in the population. If this assortment is not negligible,
a biased estimation of relative genetic and environmental contri-
butions may occur.55
Our main strengths include the use of data from the entire
population of approximately 23 million individuals, and
systematic methods to identify and ascertain ﬁrst-degree and
second-degree relatives, which allow very precise estimation of
prevalence and RRs of gout with minimal selection bias. The
virtually complete identiﬁcation of gout cases, and the use of
consistent case deﬁnitions for individuals at risk and their
relatives, ensured the absence of information bias. Furthermore,
we used prospectively recorded data for diagnosis, for construc-
tion of family relationships and for ascertaining socioeconomic
information, thus minimising recall bias and other errors
associated with self-reporting.
The present study provides quantitative estimates of familial
RR and heritability for gout in an entire population of Taiwan.
Our results conﬁrm the clinical belief that gout clusters within
families, and that genetic and environmental components con-
tribute to its aetiology. Studies of familial risk in other popula-
tions are required to determine the generalisability of these
ﬁndings to other populations.
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